Opko Health (OPK) reported quarterly earnings results on Monday, May-9-2016. The company said it had a profit of $-0.02 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.01. Analysts had a consensus of $-0.03. The company posted revenue of $291.00 million in the period, compared to analysts expectations of $266.30 million. The company’s revenue was up 866.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.26 EPS.
Many Wall Street Analysts have commented on Opko Health. Shares were Reiterated by Barrington Research on Mar 31, 2016 to “Outperform” and Lowered the Price Target to $ 16 from a previous price target of $17 .
Opko Health closed down -0.02 points or -0.21% at $9.73 with 28,39,732 shares getting traded on Friday. Post opening the session at $9.73, the shares hit an intraday low of $9.565 and an intraday high of $9.845 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
In a different news, on May 5, 2016, Gamma Investments Trust Frost (CEO) purchased 29,800 shares at $9.97 per share price. According to the SEC, on Mar 18, 2016, Jane Ph D Hsiao (Vice Chairman & CTO) purchased 1,200 shares at $10.65 per share price. On Sep 15, 2015, Adam Logal (CFO) purchased 1,000 shares at $9.95 per share price, according to the Form-4 filing with the securities and exchange commission.
OPKO Health Inc. (OPKO) is a biopharmaceutical and diagnostics company. The Company is involved in developing a range of solutions to diagnose treat and prevent various conditions including point-of-care tests laboratory developed tests (LDTs) molecular diagnostics tests and pharmaceuticals and vaccines. It operates in two segments: pharmaceutical and diagnostics. Its pharmaceutical segment consists of two operating segments pharmaceutical research and development segment and pharmaceutical operations. Its diagnostics segment consists of pathology operations and point-of-care and molecular diagnostics operations. It owns pharmaceutical operations in Chile Spain Mexico Israel Uruguay and Brazil. The product pipeline includes several pharmaceutical compounds and technologies in research and development for a range of indications and conditions.